Aim of the study: Potential care implications of antifibrotic reimbursement restrictions were studied by forced vital capacity (FVC) decline, mortality and specialty care related healthcare resource utilization in patients with idiopathic pulmonary fibrosis (IPF). Material and methods: IPF patients were identified from the electronic medical records of the Hospital District of Southwest Finland between 2005 and 2017. Text-mining was used for patient identification to exclude other interstitial lung diseases (ILD) from the cohort. FVC reimbursement restriction (FVC 50-90%) was used for stratification. Results: Out of all patients with ILD, 27% (N = 266) were identified to have IPF. At baseline, 24% presented with FVC>90% and 63% with FVC 50-90% predicted. FVC at diagnosis did not improve during the study period. Median survival decreased by severity from 6.7 years in FVC>90% at baseline to 0.7 years in patient with FVC<50% predicted. In the FVC>90% group, 14% died before a change in FVC category could be noted. Overall, 4.7 million euro worth of specialty care resources were spent on IPF patients. The highest cost driver was inpatient days. Conclusions: IPF is associated with a high burden of disease, and reimbursement restrictions are in conflict with early care. As there are antifibrotic treatment options for IPF patients, early diagnosis is important.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease causing disrupted gas exchange, respiratory failure and death [1, 2] . Disease mechanisms include genetic and environmental factors but are poorly understood [1, 2] . Substantial international efforts have unified and improved IPF diagnostics and treatment recommendations [1, [3] [4] [5] [6] [7] . The diagnosis is based on the histological and/or radiological appearance of a usual interstitial pneumonia (UIP) pattern, while excluding other interstitial lung diseases (ILD) [1, 5] .
IPF prevalence estimates vary from 2-29 cases/100 000 persons, with 8.6-19 cases/100 000 persons in Finland [1, 8, 9] . Differing study designs and historically ununiform definitions likely explain the variability in prevalence. In Finland, IPF and other ILD are diagnosed under ICD-10 code J84.1, leading to challenges in distinguishing between the diseases in retrospective studies, however, estimates are that 20-30% of these patients have IPF [9, 10] .
Due to strict inclusion and exclusion criteria, generalizing randomized clinical trial (RCT) data to real life remains challenging [11] . RCTs mainly investigated IPF patients with moderate physiological impairment, or even excluded those with forced vital capacity (FVC) >90% predicted [12] [13] [14] [15] . Although post-hoc analyses show similar antifibrotic therapy responses between patients with preserved and significantly impaired lung function, the limited nature of the data has restricted reimbursement in many countries [16, 17] . In Finland, the antifibrotic treatment reimbursement threshold is FVC 50-90% predicted [18] .
IPF associates with a substantial humanistic and healthcare burden. Yet, information on disease burden and mortality by baseline FVC category is largely lacking [19] [20] [21] [22] [23] [24] . Further, many studies assessing healthcare resource utilization (HCRU) have been claims based, leading to potential selection bias and unavailability of clinical data [19, 23, 24] . Because of reimbursement restrictions, FVC decline, mortality and HCRU are of high interest. Therefore, the aims of this study were to assess IPF progression measured by FVC decline, mortality, and healthcare resource utilization by disease severity in data reflecting real clinical practice and reimbursement restrictive categories.
Material and methods
Adult patients with ICD-10 codes for other interstitial pulmonary diseases with fibrosis or unspecified interstitial pulmonary disease (J84.1 or J84.9), at the Hospital District of Southwest Finland (HDSWF) during the years 2005-2017 were included in this retrospective registry based study (N = 993), and electronic medical records (EMR) were analysed. From the initial cohort, 266 IPF patients were identified based on high-resolution computed tomography (HRCT) and/or lung biopsy statements and clinical diagnosis. IPF patients were followed from the first J84.1 or J84.9 diagnosis (= index) until the end of 2017, the initiation of antifibrotic treatment (pirfenidone or nintedanib), death, or until lost to follow-up, defined as no specialty care contact in 18 months.
IPF cohort selection
For inclusion, fibrotic changes corresponding to IPF in HRCT or lung biopsy statements in addition to diagnosis of IPF symptoms in EMR were required. A clinical expert defined text patterns of affirmative and negative phrases for text-mining from the five most recent entries in the EMR (Table A1) . Affirmative phrases yielded one point and negative phrases against IPF reduced one point. The IPF cohort was formed using a majority vote of the affirmative or negative entries of EMR texts and imaging/pathology statements. The inclusion criteria was met by 266 patients.
IPF cohort validation
Pirfenidone and nintedanib medication, available since 2013 and 2015 in Finland respectively, was utilized for cohort validation. Of the 993 patients with J84.1 or J84.9 diagnoses, 46 were prescribed pirfenidone or nintedanib. Of these, 43 patients were among those identified with IPF. Two patients with antifibrotic medication lacked HRCT or lung biopsy required for inclusion, and one false negative case was excluded based on text-mining results (3/46, specificity 93.5%).
The specificity of the text mining algorithm was verified by selecting 20 random positively identified patients. Based on manual text validation, IPF was verified in 19 persons. In the remaining patient, IPF was the most likely diagnosis, but interstitial fibrosis due to drug adverse event was not completely excluded (1/20, specificity 95.0%). Randomly selected texts of 10 excluded patients were further assessed for sensitivity. No evident IPF cases were identified, some were clearly not IPF (e.g. cryptogenic organizing pneumonia; myelofibrosis; or scleroderma with lung involvement). This proved that both the specificity and sensitivity, along with exclusion of non-IPF patients from the cohort, were good.
Lung function
Lung function was assessed by FVC at baseline (±6 months) and during follow-up. At baseline, 62% of patients had an original structured database spirometry recording available. Text-mining of EMR increased baseline FVC value coverage to 93%. Patients were divided by baseline FVC into groups, mirroring reimbursement restrictions in Finland: (1) FVC>90% predicted; (2) FVC 50-90% predicted; (3) FVC <50% predicted. Lung function was also assessed by diffusion capacity of carbon oxide (DLCO, mmol/ min*kPa), available from structured data as an absolute value in 51% of IPF patients.
Time-to-event analyses were used to assess the change from one FVC category to the next or death. Censoring events were antifibrotic treatment initiation, end of study, or lost to follow-up. The association of FVC and DLCO was analysed with Spearman's rank correlation.
Medication
The proportion of patients receiving N-acetylcysteine, oral corticosteroid, or azathioprine was assessed from hospital prescriptions (inpatient/outpatient care) and patient texts. Medication use was defined as the time between the first and the last recording. For medication combinations, overlapping timelines were required.
Survival
Survival was assessed by Kaplan-Meier fits (stratified by baseline FVC category) and Cox-proportional hazard models. Time to event was defined from index to death (event) with initiation of antifibrotic treatment, lost to, or end of follow-up as censoring events. Survival analyses included 260 patients (exclusions: one post-mortem diagnosis, five antifibrotic treatment initiations at index). Cox-proportional hazard models included univariable and multivariable models. FVC was treated as a time varying covariate using all available measures from the follow-up. Categorical FVC groups were treated as time varying covariates and considered 'no return'. Other covariates included data ±6 months from index.
Oxygen supplementation
To investigate the need for oxygen supplementation, the lending of oxygen concentrators was assessed from the medical device lending database of the HDSWF. O 2 supplementation period included the time from the first device lending day until the device was returned.
Healthcare resource utilization and cost HCRU included specialty care contacts in the form of in-patient days, out-patient visits at the hospital, emergency room (ER) visits, procedures, surgical operations, imaging, neurophysiology, clinical physiology examinations, and laboratory tests. FVC categories were defined as no return. For each patient the time spent in each FVC category was used to map the corresponding HCRU until end of or lost to followup, antifibrotic medication initiation, or death.
Costs were computed utilizing standard HCRU unit costs from the HDSWF 2017 price listing. Each specialty care contact was evaluated by specialty and severity type (normal/demanding visit). Visits lacking these metadata were imputed as the mean costs of all corresponding visits. For prices not found at the HDSWF, other publicly available Finnish price listings were utilized. Operations, procedures, imaging and laboratory tests lacking data in any public price lists were imputed as the mean of all available corresponding prices. Costs were expressed in 2017 euros.
The Turku University Hospital administration approved the study (T76/2018) and the study was performed according to the EU General Data Protection Regulation (GDPR).
Results
Of the 993 patients with J84.1 or J84.9 diagnoses, 266 (27%) were identified as true IPF patients and included in further analyses. IPF patients were mainly identified through HRCT statements (77.1%, N = 205) or the combination of HRCT and biopsy (21.8%, N = 58), while biopsy alone was rare (1.1%, N = 3). The mean follow-up time was 3.03 (SD 2.97) years or 808 patientyears. Patients were most commonly treated with oral corticosteroids (68%) and azathioprine (11.7%), and rarely with N-acetylcysteine (2.6%). The combination of these three drugs was used by 1.1% of the patients.
The mean age at diagnosis was 74 years, with IPF more prevalent in men (64%), Table 1 . Mean FVC at index was 77% predicted, with 24% of patients presenting with FVC >90% predicted and 63% with FVC 50-90% predicted. The median number of FVC measures in the cohort was 6 (IQR [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . No trend for improved FVC at diagnosis was observed during the study period (Figure 1 ). At the end of follow-up, 16% had initiated antifibrotic medication and 42% of patients had died (Table 1) .
At baseline vs. at end of follow-up, essential hypertension was diagnosed in 33% vs. 48% of patients; chronic ischemic heart disease in 19% vs. 27%. Pneumonia diagnoses increased from 16% to 41%, and chronic obstructive pulmonary disease (COPD) from 8% to 15% (Table A2) .
FVC decline
IPF progression was described as the time from each baseline FVC category to the next. The median time from FVC>90% to below 90% or death was 2.4 years ( Table 2) . A change in category was observed in 44 (66%) of these patients and 14% died. Seventeen percent (N = 11) of patients remained in the FVC>90% category when their follow-up ended (Table 2) . Only one patient with baseline FVC>90% reached FVC<50% predicted during follow-up, one third of patients died and follow-up ended in 58% of patient before this. Moreover, 6.3% of all patients initiated antifibrotic treatment and were censored.
In patients with baseline FVC of 50-90% predicted, 18% reached an FVC<50% and 26% died. Censoring 
Mortality
The median survival of the IPF cohort was 5.0 years (95% CI: 4.0-6.7), Figure 2 . Median survival decreased by worsening FVC category from 6.7 years at baseline Table A3 , model 1). Treating FVC as a continuous variable, each percent decline increased the mortality risk by 4%. Further, in this model higher age at diagnosis and low BMI (<20 kg/m 2 ) were independently associated with mortality (Table A3 , model 2).
Healthcare resource utilization
Healthcare resource utilization correlated with disease severity. IPF patients were on average hospitalized 5.5 days per patient-year. This increased by deteriorating FVC category and was 1.2-fold higher in patients with Table A4 ). Lung transplanted patients and those lacking an FVC measure had the highest incremental costs (Figure 4 , Table A4 ). Highest cost drivers were hospital inpatient days in all categories, with an average of 2,172€ per patient-year, followed by visits and procedures (1,290€ and 1,045€ per patientyear, Table A4 ). 
Discussion
This retrospective registry study investigated 266 IPF patients during the years 2005-2017 for FVC decline, mortality and specialty care associated healthcare resource utilization. The Turku University Hospital is the sole provider of secondary care for severe respiratory diseases at the HDSWF, making data from the 480 000 catchment population representative. This study describes and defines an IPF population using data lakes for the first time. Investigating disease severity by FVC, over a period exceeding ten years, yielded insights on the disease course and healthcare resource utilization. Notably, one fourth of patients presented with mild disease and were unentitled to modern IPF treatment reimbursement.
Patient inclusion was based on positive HRCT and/or biopsy EMR results in combination with clinical diagnosis, whilst excluding other causes. This identified IPF in 27% of patients with diagnose codes J84.1 or J84.9. The proportion is consistent with previous studies showing that 20-30% of ILD patients have IPF [9, 10] .
Diagnosis over time
IPF guidelines and available treatment options have directed IPF care towards precise and earlier diagnosis [1, 5, 6 ]. Yet, no increase in FVC by year of diagnosis was observed in this study. This was surprising considering the evolution of diagnosis and the study period covering over 10 years of data, however, HRCT and biopsy criteria have been included in the diagnostic procedure in Finland since the beginning of the study period. A relatively preserved lung function at diagnosis, also seen in other Finnish studies, may partly explain this [9] . IPF diagnosis is often delayed up to 2 years from symptom onset to clinical diagnosis, by subtle progressive symptoms and non-specific clinical and physical presentation [25, 26] . Diagnosis delays independently increase mortality risk, highlighting the importance of early diagnosis [25] . Additionally, clinical studies with pirfenidone and nintedanib show that early initiation of disease modifying treatment can postpone irreversible deteriorative changes in lung function [2, 12, 13, 15] .
Oxygen supplementation and quality of life Impaired functional capacity, oxygen supplementation, and dyspnoea negatively affect the quality of life of IPF patients [27] . Unfortunately, quality of life data was not available in this study, as the 6 min walking test results were lacking for most of the patients, and the reported diffusion capacity results are more guiding in nature. Still, 13% of patients with FVC>90% received oxygen supplementation, supporting the notion that poor diffusion capacity may reduce quality of life already with mild disease. Whether they represent a sub-phenotype of IPF needs further research.
Mortality
A competing risk between FVC decline and mortality was observed. Notably, 14% of patients with baseline FVC>90% died before FVC<90% predicted was registered. Similarly, in the other baseline FVC categories one third of patients died before a change to the next category could be seen. Likely these patients represent rapid progressors [28] . Those lacking FVC data had the shortest survival, possibly explained by inability due to advanced disease, or incapacity due to morbidity, to perform spirometry. In addition to FVC, low BMI and OCS use were associated with poor survival. However, as exacerbations could not be evaluated, the context of OCS could not be assessed.
Median overall survival of IPF patients has been assessed in different studies with different methodological criteria to be 2-4 years [25, 28, 29] and 5-year survival to be 30% [30] . In this study the median overall survival for the whole cohort was 5.0 years, with 6.7 years for those with baseline FVC>90% predicted and decreasing by deteriorating lung function to 0.7 years for patients with FVC<50% predicted. In another study with differing FVC categories, mild and moderate-severe baseline FVC showed a similar trend in life-expectancy [20] . Importantly, we show a 9-fold increased mortality risk in patients with FVC <50% compared to FVC>90% predicted. Further, a 1% FVC drop was associated with a 4% increase in mortality, increasing mortality risk exponentially for each %-decline. The importance of these results is emphasized by the fact that prior survival data by baseline FVC categories are meagre.
Healthcare resource utilization
IPF progression, comorbidities and lung transplantations are key events affecting healthcare costs through hospital stays, visits and medication costs [23] . This is further supported by this study, where HCRU was mainly driven by hospital inpatient days. IPF patients presented an average of 5.5 hospital inpatients days per patient-year, in line with the previously reported 3.1-5.3 inpatient days per patient-year [19, 24] . This study also showed, for the first time, an increase in hospital inpatient days by deteriorating FVC group compared to FVC>90% predicted. Correspondingly, IPF patients had on average 10.9 outpatient visits per patient-year, increasing 1.1-fold at FVC 50-90% predicted compared to FVC>90%, and 1.2-fold for those with FVC<50%. This is in line with other claims based studies reporting outpatient visits in the range of 5.7-28 per patient-year, however these studies did not assess HCRU at different disease stages [19, 24, 31] .
Overall, HCRU costs were 5827€ per patient-year, which is a conservative estimate counting only direct specialty care related costs. Costs and mortality are substantially affected by exacerbations [21, 23, 32 ] but they could not be assessed in this study. Especially the prevalence of exacerbations at different disease severities, and their impact on HCRU and mortality will need further studies.
The strengths of the study include data collection in routine care that is not affected by strict inclusion or exclusion criteria. Further, text-mining tool utilization allowed for the exclusion of non-IPF patients from the cohort. The study period of 13 years led to a reliable assessment of mortality data.
Limitations are that as data was collected from a specific geographical region results are possibly affected by treatment praxis. However, big geographical differences are not expected, as the natural disease progression is described. Other limitations include those associated with real world data where all variables are not available for all patients. Further, incidence and prevalence were not investigated; however, this data could contribute to discussions on whether increasing IPF incidence is real or resulting from different methodologies and heterogenous patient populations [33] .
Conclusions
This study raises several considerations for the care of IPF patients in the future. First, there is still a need to improve IPF diagnosis and enhance the collaboration between primary and specialty care to detect IPF at an early stage, as no improvement in FVC at diagnosis was observed during the study period. Furthermore, FVC alone may not always be an adequate measure of disease severity, rather efforts should be made to assess the quality of life in these patients utilizing other clinical indicators. As both the economic and the humanistic burdens of disease worsen with advancing disease, it is of outmost importance to postpone FVC decline in order to increase the IPF patients' quality of life. participated in congresses with support from Boehringer Ingelheim and Sanofi Genzyme. MK has nothing to declare. TL has served as a scientific advisory board member and participated in congresses with support from GSK, Boehringer Ingelheim, AstraZeneca, Teva, Roche and MSD.
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